Company intelligence / Profile preview
Vivid Pharma Inc.
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Vivid Pharma Inc. is a private pharmaceutical company with a focus on combination therapies for headache disorders. Its lead asset, Aspirin/Sumatriptan Succinate, has completed a Phase 2 clinical trial for delayed alcohol-induced headaches. The company appears to be active and focused on translational medicine in neurology/pain management.
- Therapeutic areas
- Neurology
- Modalities
- Small molecules (combination therapy: Aspirin/Sumatriptan Succinate)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Vivid Pharma Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vivid Pharma Inc..